eMedicine Specialties > Pulmonology > Pulmonary Hypertension
Pulmonary Hypertension, Primary
Updated: Aug 13, 2009
Introduction
Background
Primary pulmonary hypertension (PPH) is a rare disease characterized by elevated pulmonary artery pressure with no apparent cause. PPH is also termed precapillary pulmonary hypertension or, more recently, idiopathic pulmonary arterial hypertension (IPAH). The diagnosis is usually made after excluding other known causes of pulmonary hypertension. Dresdale and colleagues first reported a hemodynamic account of IPAH in 1951.1 For additional resources, please visit Pulmonary Arterial Hypertension.
Pathophysiology
The pathophysiology of IPAH is poorly understood. An insult (eg, hormonal, mechanical, other) to the endothelium may occur, possibly in the setting of increased susceptibility to pulmonary vascular injury (ie, multiple hit theory), resulting in a cascade of events characterized by vascular scarring, endothelial dysfunction, and intimal and medial (smooth muscle) proliferation. At least 15-20% of patients with IPAH have a familial form, which has only recently been characterized. Some cases may be related to sporadic genetic defects. The most common genetic defect in these cases is related to the BMPR-II gene. Interestingly, in families with a familial history of PAH, only about 2.3 have an identifiable BMPR-II mutation. This suggests that additional genetic abnormalities may exist that predispose humans to developing PAH.
Early in PAH, as the pulmonary artery pressure increases because of increasing right ventricle work, thrombotic pulmonary arteriopathy occurs. Thrombotic pulmonary arteriopathy is characterized by in situ thrombosis of small muscular arteries of the pulmonary vasculature. In later stages, as the pulmonary pressure continues to rise, plexogenic pulmonary arteriopathy develops. This is characterized by a remodeling of the pulmonary vasculature with intimal fibrosis and replacement of normal endothelial structure.
Associated conditions
IPAH can be associated with portal hypertension (sometimes called portopulmonary hypertension), suggesting that patients with shunting of splanchnic blood, with or without liver disease, have a higher risk of developing PPH. Additionally, exposure of the pulmonary circulation to substances in the splanchnic circulation that normally are detoxified via the liver may contribute to the development of pulmonary hypertension. More research is necessary to better understand this relationship.
Patients with connective-tissue diseases, namely the CREST (calcinosis cutis, Raynaud phenomenon, esophageal motility disorder, sclerodactyly, and telangiectasia) variant of scleroderma, systemic lupus erythematosus, and mixed connective-tissue disease, are also predisposed to developing IPAH-like disease. This is now termed associated PAH, or APAH. However, the pathophysiologic nature of this predisposition is unclear. In the past, most experts used the term secondary pulmonary arterial hypertension for these diseases, indicating that, similar to IPAH, the process involves the precapillary circulation but is somehow caused by the underlying disease.
Other associations with IPAH include exposure to anorexigens and other alpha-adrenergic stimulants (eg, cocaine, amphetamines) and HIV seropositivity. How these associated conditions predispose to or cause PPH remains unknown.
In most cases of APAH, such as in connective-tissue disease, the prevalence of pulmonary hypertension is higher (>10% in some studies) than for IPAH, which has an incidence of 1-2 cases per million per year (see below). The true incidence of PAH in patients with connective-tissue diseases is not known.
Frequency
United States
IPAH is responsible for approximately 125-150 deaths per year and has an incidence rate of approximately 1-3 cases per million population per year. The incidence and prevalence of IPAH are considerably higher than those for pure IPAH.
International
The worldwide incidence of IPAH approximates that observed in the United States.
Mortality/Morbidity
IPAH has no cure. Untreated, IPAH leads to right-sided heart failure and death. The overall survival rate in one study was approximately 30% at 3 years. Prior to the 1990s, therapeutic options were limited. The recent emergence of prostacyclin analogues, endothelin receptor antagonists, phosphodiesterase-5 inhibitors, and other novel drug therapies has greatly improved the outlook for patients with IPAH and IPAH-like diseases. In one study, the use of long-term prostacyclin agents resulted in a 5-year mortality rate greater than 65%. With newer therapies, perhaps in combination, these figures are expected to further improve.
Race
No racial predilection is recognized.
Sex
IPAH occurs at a female-to-male ratio ranging from 2-9:1, depending on the treatment center sampled; however, the reasons for this female predilection remain unknown.
Age
Typically, younger women of childbearing age develop IPAH. However, it can also affect women in their fifth and sixth decades of life or older.
Clinical
History
The average time from symptom onset to diagnosis has been reported to be approximately 2 years. Despite recent attempts at increasing the awareness of PAH, especially APAH, this delay in diagnosis has not changed appreciably in recent years.
- Early symptoms are nonspecific. Often, neither the patient nor physician recognizes the presence of the disease, which leads to delays in diagnosis. Complicating matters, PPH requires an extensive workup in an attempt to elucidate an identifiable cause of the elevated pulmonary artery pressure.
- The most common symptoms reported in a national prospective study are as follows:
- Dyspnea is present in 60%.
- Weakness is present in 19%.
- Recurrent syncope is present in 13%.
- Women are more likely to be symptomatic than men.
Physical
Physical findings in persons with PAH can be quite variable.
- Physical examination of the cardiovascular system often reveals the following findings:
- The pulmonic component of the second heart sound is usually increased, which may demonstrate fixed or paradoxic splitting in the presence of severe right ventricular dysfunction. Occasionally, the second heart sound may be palpable.
- Pulmonic regurgitation (Graham Steell murmur) may also be apparent.
- A murmur of tricuspid regurgitation can be present, and a right ventricular lift (heave) may be noted.
- Jugular venous pulsations may be elevated in the presence of volume overload, right ventricular failure, or both. Large V waves are often present because of the commonly present severe tricuspid regurgitation.
- Other findings may include (1) hepatomegaly with palpable pulsations of the liver and (2) an abnormal abdominal-jugular reflex. Ascites is not uncommonly present in untreated patients or in patients with worsening decompensated right heart failure.
- Lung examination findings are usually normal.
- Extremity examination may reveal pitting edema of varying degrees. Patients who are bedridden may have presacral edema.
Causes
The strict definition of IPAH is pulmonary hypertension with no known cause. However, associations have been recognized (eg, connective-tissue diseases, liver cirrhosis, stimulant abuse,2 HIV infection; see Associated conditions in Pathophysiology).
More on Pulmonary Hypertension, Primary |
 Overview: Pulmonary Hypertension, Primary |
| Differential Diagnoses & Workup: Pulmonary Hypertension, Primary |
| Treatment & Medication: Pulmonary Hypertension, Primary |
| Follow-up: Pulmonary Hypertension, Primary |
| Multimedia: Pulmonary Hypertension, Primary |
| References |
| Next Page » |
References
Dresdale DT, Schultz M, Michtom RJ. Primary pulmonary hypertension. I. Clinical and hemodynamic study. Am J Med. Dec 1951;11(6):686-705. [Medline].
Abenhaim L, Moride Y, Brenot F, et al. Appetite-suppressant drugs and the risk of primary pulmonary hypertension. International Primary Pulmonary Hypertension Study Group. N Engl J Med. Aug 29 1996;335(9):609-16. [Medline].
Tolle JJ, Waxman AB, Van Horn TL, Pappagianopoulos PP, Systrom DM. Exercise-induced pulmonary arterial hypertension. Circulation. Nov 18 2008;118(21):2183-9. [Medline].
[Guideline] McGoon M, Gutterman D, Steen V, et al. Screening, early detection, and diagnosis of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. Jul 2004;126(1 Suppl):14S-34S. [Medline].
[Guideline] Rubin LJ. Diagnosis and management of pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. Jul 2004;126(1 Suppl):4S-6S. [Medline].
[Guideline] McLaughlin VV, Archer SL, Badesch DB, et al. ACCF/AHA 2009 expert consensus document on pulmonary hypertension: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents and the American Heart Association: developed in collaboration with the American College of Chest Physicians, American Thoracic Society, Inc., and the Pulmonary Hypertension Association. Circulation. Apr 28 2009;119(16):2250-94. [Medline].
Torbicki A, Kurzyna M, Kuca P, et al. Detectable serum cardiac troponin T as a marker of poor prognosis among patients with chronic precapillary pulmonary hypertension. Circulation. Aug 19 2003;108(7):844-8. [Medline].
Oudiz RJ, Farber HW. Dosing considerations in the use of intravenous prostanoids in pulmonary arterial hypertension: an experience-based review. Am Heart J. Apr 2009;157(4):625-35. [Medline].
Shapiro SM, Oudiz RJ, Cao T, et al. Primary pulmonary hypertension: improved long-term effects and survival with continuous intravenous epoprostenol infusion. J Am Coll Cardiol. Aug 1997;30(2):343-9. [Medline].
Oudiz RJ, Schilz RJ, Barst RJ, et al. Treprostinil, a prostacyclin analogue, in pulmonary arterial hypertension associated with connective tissue disease. Chest. Aug 2004;126(2):420-7. [Medline].
Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med. Mar 15 2002;165(6):800-4. [Medline].
Olschewski H, Simonneau G, Galie N, et al. Inhaled iloprost for severe pulmonary hypertension. N Engl J Med. Aug 1 2002;347(5):322-9. [Medline].
Galie N, Hinderliter AL, Torbicki A, et al. Effects of the oral endothelin-receptor antagonist bosentan on echocardiographic and doppler measures in patients with pulmonary arterial hypertension. J Am Coll Cardiol. Apr 16 2003;41(8):1380-6. [Medline].
Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. Mar 21 2002;346(12):896-903. [Medline].
[Best Evidence] Galie N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. Jun 10 2008;117(23):3010-9. [Medline].
[Best Evidence] Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med. Oct 21 2008;149(8):521-30. [Medline].
Galie N, Brundage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary arterial hypertension. Circulation. Jun 9 2009;119(22):2894-903. [Medline].
Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. Feb 15 2004;169(4):441-7. [Medline].
[Guideline] Badesch DB, Abman SH, Ahearn GS, et al. Medical therapy for pulmonary arterial hypertension: ACCP evidence-based clinical practice guidelines. Chest. Jul 2004;126(1 Suppl):35S-62S. [Medline].
[Guideline] Badesch DB, Abman SH, Simonneau G, Rubin LJ, McLaughlin VV. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest. Jun 2007;131(6):1917-28. [Medline].
[Guideline] Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology. Eur Heart J. Dec 2004;25(24):2243-78. [Medline].
Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med. Feb 1 1996;334(5):296-302. [Medline].
Gaine S. Pulmonary hypertension. JAMA. Dec 27 2000;284(24):3160-8. [Medline].
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med. Aug 1987;107(2):216-23. [Medline].
Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Exercise pathophysiology in patients with primary pulmonary hypertension. Circulation. Jul 24 2001;104(4):429-35. [Medline].
Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Gas exchange detection of exercise-induced right-to-left shunt in patients with primary pulmonary hypertension. Circulation. Jan 1 2002;105(1):54-60. [Medline].
Sun XG, Hansen JE, Oudiz RJ, Wasserman K. Pulmonary function in primary pulmonary hypertension. J Am Coll Cardiol. Mar 19 2003;41(6):1028-35. [Medline].
Further Reading
Keywords
primary pulmonary hypertension, idiopathic pulmonary arterial hypertension, IPAH, idiopathic pulmonary hypertension, elevated pulmonary artery pressure, thrombotic pulmonary arteriopathy, TPA, plexogenic pulmonary arteriopathy, PPH, precapillary pulmonary hypertension, endothelin receptor antagonists, ERAs, endothelin-receptor antagonists, pulmonary hypertension, portal hypertension, pulmonary arteriopathy, pulmonary artery hypertension, PAH, pulmonary arterial hypertension, portopulmonary hypertension, CREST syndrome
